TRPV4 and hepatocellular carcinoma: As a result, the TRPV4 inhibitor GL-V9 inactivates the AMPK/MLC/ERM axis of suspended HCC cells, suppressing sc polarity, adhesion to HUVEC and transendothelial migration.